|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2021 L Street NW, Suite 900 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20036 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 59171-12
|
||||||||
|
6. House ID# 352060000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Suzanne M. Leous |
Date | 1/20/2023 4:28:21 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Public health program funding
Federal research funding
Emergency funding for COVID therapeutics
Research Investment to Spark the Economy (RISE) Act (H.R. 869/S. 289)
Cures 2.0 Act (H.R. 6000)
Advanced Research Projects Agency for Health (ARPA-H)
FY 2023 NIH funding
FY 2023 AHRQ funding
FY 2023 CDC funding
FY 2023 funding for CDC Sickle Cell Data Collection program
FY 2023 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (H.R. 8295/S. 4659)
FY2023 Further Continuing Appropriations Act (through 12/23/2022) (H.R. 1437)
FY2023 Further Additional Continuing Appropriations Act (through 12/30/2022) (H.R. 4373)
FY2023 Consolidated Appropriations Act (H.R. 2617)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA), President of the U.S.
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
|
Suzanne |
Leous |
MPA |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Sickle cell disease/trait issues
Hematology/oncology treatment issues
Hematology/oncology drug research and approval issues
General hematology public health and research issues
Emergency funding for COVID therapeutics
Research Investment to Spark the Economy (RISE) Act (H.R. 869/S. 289)
Open access policy for peer reviewed research journals
Issues impacting blood supply shortages/safety
Issues related to convalescent plasma
Issues impacting delivery of bone marrow, peripheral blood, and cord blood
Issues related to implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136)
Issues related to health equity/disproportionate impact of COVID-19 on minority populations
COVID-19 vaccination policies/prioritization
Clinical trials regulations and coverage
Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training
Cures 2.0 Act (H.R. 6000)
Advanced Research Projects Agency for Health (ARPA-H)
Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (S. 2706 / H.R. 5030)
Meaningful Access to Federal Health Plan Claims Data Act (H.R. 5394)
Health Equity and Accountability Act (H.R. 7585)
Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 4128/S. 2209)
Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), President of the U.S.
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Roades |
|
|
|
Suzanne |
Leous |
MPA |
|
|
Stephanie |
Kaplan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Coverage of blood transfusions under Medicare Hospice Benefit
Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566)
Issues related to CAR-T/cellular and gene therapies
Implementation of the Medicare Access and CHIP Reauthorization Act pf 2015 (P.L. 114-10)
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148)
CMS national coverage determinations
Medicaid coverage for sickle cell disease
Issues impacting opioid access/use for patients with hematologic disease and disorders
Issues related to implementation of Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136)
Issues related to health equity/disproportionate impact of COVID-19 on minority populations
Issues related to telemedicine/telehealth
COVID-19 vaccination policies/prioritization
Resident Physician Shortage Reduction Act (H.R. 2256/S. 834)
Healthcare Workforce Resilience Act (H.R. 2255/S. 1024)
Cures 2.0 Act (H.R. 6000)
Sickle cell disease/trait issues
Sickle Cell Disease Comprehensive Care Act (H.R. 6216 / S.3389)
Prior authorization
Improving Seniors Timely Access to Care Act (H.R. 3173/S. 3018)
Advancing Telehealth Beyond COVID Act (H.R. 4040)
Supporting Medicare Providers Act (H.R. 8800)
FY2023 Consolidated Appropriations Act (H.R. 2617)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Resident Physician Shortage Reduction Act (H.R. 2256/S. 834)
Healthcare Workforce Resilience Act (H.R. 2255/S. 1024)
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148)
Hematology/oncology drug research and approval issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144)
Clinical trials regulations and coverage
Issues impacting coverage for hematologic diseases and conditions
Issues related to CAR-T/cellular and gene therapies
Issues impacting opioid access/use for patients with hematologic disease and disorders
Issues impacting blood supply shortages/safety
Issues related to convalescent plasma
Issues related to health equity/disproportionate impact of COVID-19 on minority populations
Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training
Cures 2.0 Act (H.R. 6000)
Implementation of No Surprises Act (P.L. 116-260)
Cancer Patient Equity Act of 2021 (H.R.5377)
HELP Copays Act (H.R. 5801)
Cancer Drug Parity Act of 2021 (H.R. 4385 / S. 3080)
Sickle cell disease/trait issues
Sickle Cell Disease Comprehensive Care Act (H.R. 6216 / S.3389)
Impact of climate change on health
Resolution expressing support for healthcare personnel and condemning assaults on healthcare personnel as the U.S. healthcare system faces unprecedented staffing shortages and increased workplace-related stressors (H.Res. 909)
Sickle Cell Care Expansion Act (H.R. 7177/S.4425)
Women's Health Protection Act (S. 1975/ H.R. 3755/S. 4132)
Newborn Screening Saves Lives Reauthorization Act (H.R. 482/S. 350)
Prior authorization
Improving Seniors Timely Access to Care Act (H.R. 3173/S. 3018)
Health Equity and Accountability Act (H.R. 7585)
Issues related to maternal health care and abortion access
Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 4128/S. 2209)
Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348)
Affordability of employer coverage for family members/"family glitch
Sickle Cell Disease Treatment Centers Act of 2022 (S. 4866/ H.R. 8855)
Advancing Telehealth Beyond COVID Act (H.R. 4040)
Resolution supporting the designation of September 2022 as "Sickle Cell Disease Awareness Month" (H.Res.1330/S.Res.868)
Let Doctors Provide Reproductive Health Care Act (S. 4723/H.R. 8650)
FY2023 Consolidated Appropriations Act (H.R. 2617)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |